277 related articles for article (PubMed ID: 18839071)
1. Correlation between the levels of survivin and survivin promoter-driven gene expression in cancer and non-cancer cells.
Konopka K; Spain C; Yen A; Overlid N; Gebremedhin S; Düzgüneş N
Cell Mol Biol Lett; 2009; 14(1):70-89. PubMed ID: 18839071
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of TTR and CMV promoters in vivo and in vitro via a secreted luciferase reporter system].
Luo ST; Tian WH; Wang G; Dong XY; Yang L; Wu XB
Bing Du Xue Bao; 2009 Nov; 25(6):424-9. PubMed ID: 20077932
[TBL] [Abstract][Full Text] [Related]
4. [Detection and comparison of transcriptional activities of tumor-specific survivin and alpha-fetoprotein promoters in human hepatocellular carcinoma cells].
Kuang G; Huang AL; Tang N
Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):440-2. PubMed ID: 15975279
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
Zhu ZB; Makhija SK; Lu B; Wang M; Kaliberova L; Liu B; Rivera AA; Nettelbeck DM; Mahasreshti PJ; Leath CA; Barker S; Yamaoto M; Li F; Alvarez RD; Curiel DT
Cancer Gene Ther; 2004 Apr; 11(4):256-62. PubMed ID: 15017380
[TBL] [Abstract][Full Text] [Related]
6. Cre-loxP system as a versatile tool for conferring increased levels of tissue-specific gene expression from a weak promoter.
Nakamura S; Watanabe S; Ohtsuka M; Maehara T; Ishihara M; Yokomine T; Sato M
Mol Reprod Dev; 2008 Jun; 75(6):1085-93. PubMed ID: 18163444
[TBL] [Abstract][Full Text] [Related]
7. Cancer-specific activation of the survivin promoter and its potential use in gene therapy.
Chen JS; Liu JC; Shen L; Rau KM; Kuo HP; Li YM; Shi D; Lee YC; Chang KJ; Hung MC
Cancer Gene Ther; 2004 Nov; 11(11):740-7. PubMed ID: 15359286
[TBL] [Abstract][Full Text] [Related]
8. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
9. Activation of cancer-specific gene expression by the survivin promoter.
Bao R; Connolly DC; Murphy M; Green J; Weinstein JK; Pisarcik DA; Hamilton TC
J Natl Cancer Inst; 2002 Apr; 94(7):522-8. PubMed ID: 11929953
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter.
Harms JS; Splitter GA
Hum Gene Ther; 1995 Oct; 6(10):1291-7. PubMed ID: 8590733
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.
Ulasov IV; Rivera AA; Sonabend AM; Rivera LB; Wang M; Zhu ZB; Lesniak MS
Cancer Biol Ther; 2007 May; 6(5):679-85. PubMed ID: 17404502
[TBL] [Abstract][Full Text] [Related]
12. [Anti-tumor effect of suicide gene therapy using chimeric promoter plus radiotherapy on cancer cell lines].
Sun WJ; Xiong J; Wang WF; Liao ZK; Zhou FX; Zhou YF
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):245-50. PubMed ID: 21575492
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tumor-specific promoter activities in melanoma.
Lu B; Makhija SK; Nettelbeck DM; Rivera AA; Wang M; Komarova S; Zhou F; Yamamoto M; Haisma HJ; Alvarez RD; Curiel DT; Zhu ZB
Gene Ther; 2005 Feb; 12(4):330-8. PubMed ID: 15696177
[TBL] [Abstract][Full Text] [Related]
14. Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax.
Garg H; Salcedo R; Trinchieri G; Blumenthal R
Cancer Gene Ther; 2010 Mar; 17(3):155-63. PubMed ID: 19816523
[TBL] [Abstract][Full Text] [Related]
15. Serum decreases the size of Metafectene-and Genejammer-DNA complexes but does not affect significantly their transfection activity in SCCVII murine squamous cell carcinoma cells.
Konopka K; Overlid N; Nagaraj AC; Düzgüneş N
Cell Mol Biol Lett; 2006; 11(2):171-90. PubMed ID: 16847564
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells.
Kim KI; Kang JH; Chung JK; Lee YJ; Jeong JM; Lee DS; Lee MC
J Nucl Med; 2007 Sep; 48(9):1553-61. PubMed ID: 17704247
[TBL] [Abstract][Full Text] [Related]
17. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression.
Liu BH; Wang X; Ma YX; Wang S
Gene Ther; 2004 Jan; 11(1):52-60. PubMed ID: 14681697
[TBL] [Abstract][Full Text] [Related]
18. [Effects of human telomerase reverse transcriptase promoter and survivin promoter in targeted tumor gene therapy].
Zhang Y; Ma H; Liu SL; Liu YX; Zheng DX
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(7):475-9. PubMed ID: 18642790
[TBL] [Abstract][Full Text] [Related]
19. [Detection of transcriptional activities of tumor-specific survivin promoter in human prostatic carcinoma].
Luo XM; Liu JY; Su MQ; Hao XK
Zhonghua Nan Ke Xue; 2007 Jun; 13(6):502-6. PubMed ID: 17615972
[TBL] [Abstract][Full Text] [Related]
20. [Study on apoptosis of oral squamous carcinoma cell line KB and KBv200 induced by survivin RNAi].
Yan L; Chen WQ; Liang YJ; Dai CL; Wang XH; Shi Z; Chen LM; Fu LW
Ai Zheng; 2006 Aug; 25(8):933-40. PubMed ID: 16965671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
